Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Zachary S Wallace, Guy Katz, Yasmin G Hernandez-Barco, Matthew C Baker
IgG4-related disease (IgG4-RD) is an increasingly recognized cause of fibroinflammatory lesions in patients of diverse racial and ethnic backgrounds and is associated with an increased risk of death. The aetiology of IgG4-RD is incompletely understood, but evidence to date suggests that B and T cells are important players in pathogenesis, both of which are key targets of ongoing drug development programmes. The diagnosis of IgG4-RD requires clinicopathological correlation because there is no highly specific or sensitive test...
2024: Rheumatology Advances in Practice
#22
REVIEW
Yuandani, Ibrahim Jantan, Emil Salim, Abdi Wira Septama, Kamal Rullah, Firzan Nainu, Mohd Fadhlizil Fasihi Mohd Aluwi, Talhah Bin Emran, Miah Roney, Nur Aini Khairunnisa, Halimah Raina Nasution, Muh Fadhil As'ad, Nur Farisya Shamsudin, Maryam Aisyah Abdullah, Haya Luthfiyyah Marwa Rani, Diany Mahabbah Al Chaira, Nabila Aulia
The anti-inflammatory and immunosuppressive activities of plant secondary metabolites are due to their diverse mechanisms of action against multifarious molecular targets such as modulation of the complex immune system associated with rheumatoid arthritis (RA). This review discussed and critically analyzed the potent anti-inflammatory and immunosuppressive effects of several phytochemicals and their underlying mechanisms in association with RA in experimental studies, including preliminary clinical studies of some of them...
April 10, 2024: Phytotherapy Research: PTR
#23
REVIEW
Hung-Yang Kuo, Kabir A Khan, Robert S Kerbel
Antiangiogenic agents, generally antibodies or tyrosine-kinase inhibitors that target the VEGF-VEGFR pathway, are currently among the few combination partners clinically proven to improve the efficacy of immune-checkpoint inhibitors (ICIs). This benefit has been demonstrated in pivotal phase III trials across different cancer types, some with practice-changing results; however, numerous phase III trials have also had negative results. The rationale for using antiangiogenic drugs as partners for ICIs relies primarily on blocking the multiple immunosuppressive effects of VEGF and inducing several different vascular-modulating effects that can stimulate immunity, such as vascular normalization leading to increased intratumoural blood perfusion and flow, and inhibition of pro-apoptotic effects of endothelial cells on T cells, among others...
April 10, 2024: Nature Reviews. Clinical Oncology
#24
JOURNAL ARTICLE
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
BACKGROUND: Glioblastoma (GBM), a highly immunosuppressive and often fatal primary brain tumor, lacks effective treatment options. GBMs contain a subpopulation of GBM stem-like cells (GSCs) that play a central role in tumor initiation, progression, and treatment resistance. Oncolytic viruses, especially oncolytic herpes simplex virus (oHSV), replicate selectively in cancer cells and trigger antitumor immunity-a phenomenon termed the "in situ vaccine" effect. Although talimogene laherparepvec (T-VEC), an oHSV armed with granulocyte macrophage-colony stimulating factor (GM-CSF), is Food and Drug Administration (FDA)-approved for melanoma, its use in patients with GBM has not been reported...
April 9, 2024: Journal for Immunotherapy of Cancer
#25
JOURNAL ARTICLE
Naoto Azuma, Masaru Natsuaki, Naoaki Hashimoto, Takeo Abe, Suzu Ueda, Yuko Ohno, Masatoshi Jinnin, Kiyoshi Matsui
Alopecia associated with lupus erythematosus is broadly classified into reversible nonscarring alopecia seen in the acute phase, such as worsening of systemic lupus erythematosus (SLE) and cicatricial alopecia seen in chronic cutaneous lupus erythematosus represented by discoid lupus erythematosus (DLE). In DLE-induced alopecia, early therapeutic intervention before developing scarring alopecia is important, but the condition is often resistant to conventional treatment. Anifrolumab (ANI), a novel therapeutic agent for SLE that inhibits type I interferon activity, has been shown to be effective against acute skin lesions, including alopecia, in patients with SLE...
April 10, 2024: Modern rheumatology case reports
#26
JOURNAL ARTICLE
Vishal Gupta, Rhea Ahuja, Tekumalla Sindhuja, Shafaque Imran, Ganesh Kumar Viswanathan, Manoj Kumar Tembhre, Shivam Pandey, Sujay Khandpur
Background Paradoxical flare of pemphigus following rituximab infusion has been reported previously, however, its incidence or risk factors have not been studied in detail. Objectives To evaluate the clinical and immunological predictors associated with post-rituximab paradoxical pemphigus flare. Materials and Methods This was a prospective cohort study including adult patients with pemphigus vulgaris or foliaceus who were treated with rituximab. Patients were administered 1000 mg of intravenous rituximab on days 0 and 14 (Rheumatoid arthritis (RA) protocol), with or without oral prednisolone and/or conventional immunosuppressive agents...
March 7, 2024: Indian Journal of Dermatology, Venereology and Leprology
#27
JOURNAL ARTICLE
Qin Liu, Rui Xu, Jingwen Shen, Yaping Tao, Jingyi Shao, Yaohua Ke, Baorui Liu
BACKGROUND: Chemoimmunotherapy has shown promising advantages of eliciting immunogenic cell death and activating anti-tumor immune responses. However, the systemic toxicity of chemotherapy and tumor immunosuppressive microenvironment limit the clinical application. METHODS: Here, an injectable sodium alginate hydrogel (ALG) loaded with nanoparticle albumin-bound-paclitaxel (Nab-PTX) and an immunostimulating agent R837 was developed for local administration. Two murine hepatocellular carcinoma and breast cancer models were established...
April 9, 2024: Journal of Translational Medicine
#28
JOURNAL ARTICLE
Yuwaraj Kadariya, Eleonora Sementino, Maggie Ruan, Mitchell Cheung, Parham Hadikhani, Hatice U Osmanbeyoglu, Andres J Klein-Szanto, Kathy Cai, Joseph R Testa
UNLABELLED: Asbestos and BAP1 germline mutations are risk factors for malignant mesothelioma (MM). While it is well accepted that amphibole asbestos is carcinogenic, the role of serpentine (chrysotile) asbestos in MM has been debated. To address this controversy, we assessed whether minimal exposure to chrysotile could significantly increase the incidence and rate of MM onset in germline Bap1-mutant mice. With either crocidolite or chrysotile, and at each dose tested, MMs occurred at a significantly higher rate and earlier onset time in Bap1-mutant mice than in wild-type littermates...
April 8, 2024: Cancer Res Commun
#29
JOURNAL ARTICLE
Habib Qaiser, Irshad Bajeer, Sabeeta Khatri, Seema Hashmi, Ali Asghar Lanewala
OBJECTIVE: To determine the clinico-pathological features and long-term outcome of secondary steroid-resistant nephrotic syndrome treated with steroids and calcineurin inhibitors. METHODS: The retrospective cohort study was conducted at the Sindh Institute of Urology and Transplant, Karachi, in June and July 2023, and comprised data from January 1, 2008, to December 31, 2020, of children aged 1-18 years who developed steroid resistance after initial sensitivity to steroids with at least 1-year of follow-up...
March 2024: JPMA. the Journal of the Pakistan Medical Association
#30
JOURNAL ARTICLE
Ayush Pant, Brandon Hwa-Lin Bergsneider, Siddhartha Srivastava, Timothy Kim, Aanchal Jain, Sadhana Bom, Pavan Shah, Nivedha Kannapadi, Kisha Patel, John Choi, Kwang Bog Cho, Rohit Verma, Caren Yu-Ju Wu, Henry Brem, Betty Tyler, Drew M Pardoll, Christina Jackson, Michael Lim
Immunotherapy has revolutionized the treatment of cancers. Reinvigorating lymphocytes with checkpoint blockade has become a cornerstone of immunotherapy for multiple tumor types, but the treatment of glioblastoma has not yet shown clinical efficacy. A major hurdle to treat GBM with checkpoint blockade is the high degree of myeloid-mediated immunosuppression in brain tumors that limits CD8 T-cell activity. A potential strategy to improve anti-tumor efficacy against glioma is to use myeloid-modulating agents to target immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment...
2024: Oncoimmunology
#31
JOURNAL ARTICLE
Xiaoying Zhang, Lingfeng Zhang, Yun Li, Na Wang, Yicheng Zhang
BACKGROUND: Timely diagnosis and appropriate antifungal therapy are critical for improving the prognosis of patients with invasive fungal disease (IFD) after hematopoietic stem cell transplantation (HSCT). We evaluated the performance of metagenomic next-generation sequencing (mNGS) and conventional microbiological testing (CMT), as well as the diagnosis, therapeutic management, and outcomes of IFD after HSCT. METHODS: We retrospectively studied 189 patients who underwent HSCT and were considered at risk for IFD...
2024: Frontiers in Cellular and Infection Microbiology
#32
REVIEW
Matthew J Townsend, Isaac J Benque, Michael Li, Shilpa Grover
BACKGROUND: Immune checkpoint inhibitors (ICIs) are effective oncologic agents which frequently cause immune-related adverse events (irAEs) which can impact multiple organ systems. Onco-Gastroenterology is a novel and emerging subspecialty within gastroenterology focused on cancer treatment-related complications. Gastroenterologists must be prepared to identify and manage diverse immune-mediated toxicities including enterocolitis, hepatitis, pancreatitis and other ICI-induced toxicities...
April 8, 2024: Alimentary Pharmacology & Therapeutics
#33
Salvatore Rotundo, Maria Teresa Tassone, Nadia Marascio, Helen Linda Morrone, Simona Gigliotti, Angela Quirino, Alessandro Russo, Giovanni Matera, Enrico Maria Trecarichi, Carlo Torti
BACKGROUND: Cutaneous bacillary angiomatosis (cBA) is a vascular proliferative disorder due to Bartonella spp. that mostly affects people living with HIV (PLWH), transplanted patients and those taking immunosuppressive drugs. Since cBA is mostly related to these major immunocompromising conditions (i.e., T-cell count impairment), it is considered rare in relatively immunocompetent patients and could be underdiagnosed in them. Moreover, antimicrobial treatment in this population has not been previously investigated...
April 8, 2024: BMC Infectious Diseases
#34
REVIEW
Iñigo Rua-Figueroa, M Jesus García de Yébenes, Julia Martinez-Barrio, Maria Galindo Izquierdo, Jaime Calvo Alén, Antonio Fernandez-Nebro, Raúl Menor-Almagro, Loreto Carmona, Beatriz Tejera Segura, Eva Tomero, Mercedes Freire-González, Clara Sangüesa, Loreto Horcada, Ricardo Blanco, Esther Uriarte Itzazelaia, Javier Narváez, José Carlos Rosas Gómez de Salazar, Silvia Gómez-Sabater, Claudia Moriano Morales, Jose L Andreu, Vicente Torrente Segarra, Elena Aurrecoechea, Ana Perez, Javier Nóvoa Medina, Eva Salgado, Nuria Lozano-Rivas, Carlos Montilla, Esther Ruiz-Lucea, Marta Arevalo, Carlota Iñiguez, María Jesús García-Villanueva, Lorena Exposito, Mónica Ibáñez-Barceló, Gema Bonilla, Irene Carrión-Barberà, Celia Erausquin, Jorge Juan Fragio Gil, Angela Pecondón, Francisco J Toyos, Tatiana Cobo, Alejandro Muñoz-Jiménez, Jose Oller, Joan M Nolla, J M Pego-Reigosa
OBJECTIVE: To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate it in a large multicentre lupus cohort. METHODS: We used data from the prospective phase of RELESSER (RELESSER-PROS), the SLE register of the Spanish Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLESIS score, plus all other potential predictors identified in a literature review...
April 8, 2024: Lupus Science & Medicine
#35
JOURNAL ARTICLE
Ting Zhang, Xing-Yan Luo, Lin Jing, Chunfen Mo, Huijie Guo, Shuxia Yang, Yantang Wang, Ketian Zhao, Yi Lai, Yang Liu
In recent years, immunosuppressants have shown significant success in the treatment of autoimmune diseases. Therefore, there is an urgent need to develop additional immunosuppressants that offer more options for patients. Toosendanin has been shown to have immunosuppressive activity in vitro as well as effects on autoimmune hepatitis (AIH) in vivo. Toosendanin did not induce apoptosis in activated T-cells but did affect the survival rate of naive T-cells. Toosendanin did not affect the expression of CD25 or secretion of IL-2 by activated T-cells, and not affect the expression of IL-4 and INF-γ...
April 6, 2024: European Journal of Pharmacology
#36
JOURNAL ARTICLE
Natasha S Bala, Courtney D Thornburg
Strides in advancements of care of persons with hemophilia include development of long-acting factor replacement therapies, novel substitution and hemostatic rebalancing agents, and most recently approved gene therapy. Several decades of preclinical and clinical trials have led to development of adeno-associated viral (AAV) vector-mediated gene transfer for endogenous production of factor VIII (FVIII) in hemophilia A (HA). Only one gene therapy product for HA (valoctocogene roxaparvovec) has been approved by regulatory authorities...
April 8, 2024: Seminars in Thrombosis and Hemostasis
#37
JOURNAL ARTICLE
Caroline H Siegel, Lisa R Sammaritano
IMPORTANCE: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and immune-mediated injury to multiple organ systems, including the mucocutaneous, musculoskeletal, hematologic, and kidney systems. Approximately 3.4 million people worldwide have received a diagnosis of SLE. OBSERVATIONS: Approximately 90% of people with SLE are female. Although there are no uniformly accepted diagnostic criteria for SLE, the 2019 European Alliance of Associations for Rheumatology (formerly the European League Against Rheumatism)/American College of Rheumatology classification criteria developed for scientific study are an estimated 96...
April 8, 2024: JAMA
#38
JOURNAL ARTICLE
Hiroki Kaneko, Yoshinori Ozono, Hisayoshi Iwakiri, Hiroshi Hatada, Naomi Uchiyama, Yuri Komaki, Kenichi Nakamura, Satoru Hasuike, Kenji Nagata, Hiroshi Kawakami
Hepatitis C virus (HCV) reactivation has been reported to be caused due to several anticancer drugs and immunosuppressive agents; however, HCV reactivation after steroid monotherapy has rarely been reported. Here, we report the case of a 65-year-old Japanese man with HCV infection who developed HCV reactivation after the administration of prednisolone (PSL) for 6 days for sudden deafness. In the patient history, the positivity for anti-HCV antibody was observed, but serum level of HCV RNA was not measured...
April 8, 2024: Clinical Journal of Gastroenterology
#39
REVIEW
Muggunna Balasubramaniam, Sarah Sapuan, Ilie Fadzilah Hashim, Nurul Izza Ismail, Amira Suriaty Yaakop, Nur Azzalia Kamaruzaman, Ana Masara Ahmad Mokhtar
Herbal treatments have been utilized for millennia to cure a variety of ailments. There are over 20, 000 herbal remedies available to treat cancer and other disease in humans. In Ayurveda, traditional plants having revitalizing and nourishing characteristics are known as "Rasayanas." They have anti-inflammatory, anticancer, anti-microbicidal, antiviral, and immunomodulatory effects on the immune system. Immunomodulation is a mechanism through which the body stimulates, suppresses, or boosts the immune system to maintain homeostasis...
April 15, 2024: Heliyon
#40
JOURNAL ARTICLE
Mustafa Kayabaşı, Işıl Kefeli, Pınar Çakar Özdal, Ali Osman Saatci
INTRODUCTION: A case of ocular bartonellosis under anti-tumour necrosis factor treatment is described. CASE DESCRIPTION: A 29-year-old woman with psoriasis who had been on certolizumab treatment was examined with a left visual deterioration following a fever bout, malaise, and placoid erythematous rashes on her neck. As there was acute anterior uveitis in her left eye, it was recommended to stop certolizumab treatment for a possible infectious aetiology. However, her physician elected to continue the certolizumab treatment...
2024: European Journal of Case Reports in Internal Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
